AMRN · AMARIN CORP PLC\UK

🧪 Trial & FDA Catalysts

• Dec 2025 · Phase 1 · Results Expected · Bioequivalence and Adhesion of a Rotigotine Patch in Healthy Subjects
  Registry primary completion date, not a results date
• May 2018 · Phase 3 · Results Expected · A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Pat
  Registry primary completion date, not a results date
• Feb 2011 · Phase 3 · Results Expected · Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins W
  Registry primary completion date, not a results date
• Oct 2010 · Phase 3 · Results Expected · Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (
  Registry primary completion date, not a results date
• Aug 2007 · Phase 3 · Results Expected · TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Dise
  Registry primary completion date, not a results date

📊 Drug Pipeline

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AMRN holds $314.6M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

• No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMRN files for a raise →

👥 Who Owns AMRN

Share count 380,694 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.